SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy for CLL shows promise in small japanese study
Disease control CompletedThis completed phase 2 study tested two drug combinations—venetoclax plus obinutuzumab or venetoclax plus ibrutinib—in 20 Japanese adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well these combinati…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC